Objective-ATP-binding cassette transporter A1 (ABCA1) exerts an atheroprotective action through the biogenesis of highdensity lipoprotein in hepatocytes and prevents the formation of foam cells from macrophages. Controlling ABCA1 is a rational approach to improving atherosclerotic cardiovascular disease. Although much is known about the regulatory mechanism of ABCA1 synthesis, the molecular mechanism underpinning its degradation remains to be clearly described. Approach and Results-ABCA1 possesses potential sites of phosphorylation by serine/threonine-protein kinase Pim-1 (Pim-1). Pim-1 depletion decreased the expression of cell surface-resident ABCA1 (csABCA1) and apolipoprotein A-I-mediated [ 3 H]cholesterol efflux in the human hepatoma cell line HepG2, but not in peritoneal macrophages from mice. In vitro kinase assay, immunoprecipitation, and immunocytochemistry suggested phosphorylation of csABCA1 by the long form of Pim-1 (Pim-1L). Cell surface biotinylation indicated that Pim-1L inhibited lysosomal degradation of csABCA1 involving the liver X receptor β, which interacts with csABCA1 and thereby protects it from ubiquitination and subsequent lysosomal degradation. Cell surface coimmunoprecipitation with COS-1 cells expressing extracellularly hemagglutinin-tagged ABCA1 showed that Pim-1L-mediated phosphorylation of csABCA1 facilitated the interaction between csABCA1 and liver X receptor β and thereby stabilized the csABCA1-Pim-1L complex. Mice deficient in Pim-1 kinase activity showed lower expression of ABCA1 in liver plasma membranes and lower plasma high-density lipoprotein levels than control mice. Conclusions-Pim-1L protects hepatic csABCA1 from lysosomal degradation by facilitating the physical interaction between csABCA1 and liver X receptor β and subsequent stabilization of the csABCA1-Pim-1L complex and thereby regulates the circulating level of high-density lipoprotein. Our findings may aid the development of high-density lipoproteintargeted therapy. (Arterioscler Thromb Vasc Biol.
A TP-binding cassette transporter A1 (ABCA1) promotes the apolipoprotein A-I-mediated efflux of cellular cholesterol and phospholipids. [1] [2] [3] [4] Its hepatic and intestinal function is critical for the biogenesis of high-density lipoprotein (HDL), a protective factor for arteriosclerosis, and determines circulating HDL levels. 5, 6 HDL mediates reverse cholesterol transport, a process resulting in the net movement of cholesterol from peripheral tissues back to the liver, and it inhibits lipid oxidation, restores endothelial function, and exerts anti-inflammatory and antiapoptotic action. 7 These properties could confer an antiatherogenic capacity to HDL and inhibit atherosclerosis. ABCA1 in peripheral cells contributes to reverse cholesterol transport by releasing cellular cholesterol extracellularly to HDL in a sequential collaborative reaction with the ATP-binding cassette transporter G1 (ABCG1). [8] [9] [10] Impaired cholesterol efflux by both transporters in macrophages induces the accumulation of cellular cholesterol, foam cell formation, and the subsequent progression to atherogenesis. 11, 12 The atheroprotective function of ABCA1 in humans is illustrated by Tangier disease, which is caused by a mutation in the gene for ABCA1 and is characterized by a near absence of circulating HDL. [1] [2] [3] [4] Some Tangier kindred show an increased susceptibility to atherosclerotic cardiovascular disease. This background has generated great interest in treating atherosclerotic cardiovascular disease by controlling ABCA1.
Cellular expression of ABCA1 is regulated at the transcriptional and post-transcriptional levels. Cellular cholesterol homeostasis strictly controls the transcription of ABCA1 involving liver X receptor (LXR) in the peripheral cells. 13 miR-33 embedded within introns of the genes for SREBP (sterol regulatory element-binding protein) targets ABCA1 transcription, decreasing the abundance of ABCA1 and circulating HDL levels. 14, 15 In contrast to the growing body of information regarding the regulation of ABCA1 mRNA, the molecular mechanism underlying the degradation of ABCA1 remains elusive. Although in vitro and animal studies using inhibitors of the protease calpain and proteasome suggest that they cleave and degrade ABCA1, [16] [17] [18] [19] the molecular entity of calpain and the molecular mechanism of the degradation of ABCA1 involving proteasome have not yet been clearly described. On the basis of the report by Hozoji et al 20 that LXRβ interacts with and post-translationally modulates ABCA1, we recently found that LXRβ protects the cell surface-resident ABCA1 (csABCA1) from ubiquitination through its physical interaction with csABCA1 and not through its transcriptional activity, which prevents lysosomal degradation of csABCA1 through the endosomal sorting complex required for transport (ESCRT) system. 21, 22 This mechanism mediates ABCA1 degradation independently of the pathway involving calpain and proteasome. To gain further insight into this finding, the current study focuses on phosphorylation because phosphorylation can be used to modulate the nature and the strength of protein-protein interactions, thereby regulating protein binding. 23, 24 ABCA1 has deduced consensus phosphorylation sites (-K/R-K/R-R-K/R-X-S/T-) in the cytosolic region for serine/threonine-protein kinase Pim-1 (Pim-1) encoded by PIM1, a proto-oncogene that is highlighted in research on multiple human malignancies. 25, 26 The activity of Pim-1 is correlated with its cellular expression because it is constitutively active kinase. 27 Pim-1 is produced as short and long isoforms (Pim-1S, 33 kDa; Pim-1L, 44 kDa) by alternative translation initiation sites, 28 both of which exhibit comparable in vitro kinase activity. 28 The 2 isoforms of Pim-1 differ in cellular localization in that Pim-1S is present in the cytosol and nucleus, whereas Pim-1L is primarily localized to the plasma membrane. [29] [30] [31] Therefore, Pim-1S and Pim-1L are considered to regulate distinct substrates. Although the cellular function of Pim-1L has been much less extensively studied than that of Pim-1S, Pim-1L is suggested to form a complex with other cellular components. 28 Indeed, Pim-1L phosphorylates ABCG2 (an ABC transporter that mediates the efflux of various drugs) and increases its expression; it also confers drug resistance to a prostate cancer cell line. 31 This prompts us to examine the implication of Pim-1L in the modulation of csABCA1.
In the present study, we show by using the human hepatoma cell line HepG2, mouse macrophages, and Pim-1 kinase activity-deficient mice that Pim-1L interacts and phosphorylates csABCA1, which facilitates the interaction between csABCA1 and LXRβ, retards degradation of csABCA1, and consequently regulates the abundance of csABCA1 and circulating HDL. This mechanism could underpin the hepatocytespecific response of csABCA1 because Pim-1L is expressed at a much higher level in hepatocytes than in macrophages.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Decreased Expression and Function of ABCA1 by Pim-1 Depletion in HepG2 Cells but not in Mouse Peritoneal Macrophages
The influence of Pim-1 on the expression and function of ABCA1 was explored in human hepatoma HepG2 cells and mouse peritoneal macrophages (MPMs), both of which express ABCA1 endogenously. Transfection with Pim-1 short interfering RNA (siRNA) markedly suppressed signal intensity of 3 bands that could be detected in HepG2 cells by antibody against Pim-1 ( Figure 1A ) and of 2 of the 3 bands in MPM ( Figure IA in the online-only Data Supplement), indicating that all 3 bands in HepG2 cells and the lower 2 bands in MPM represent Pim-1. Under this condition, the expression of ABCA1 in the cell lysates and surface fractions was decreased significantly in HepG2 cells, but not in MPMs. In HepG2 cells, Pim-1 depletion decreased the abundance of ABCA1 by 65% in the cell lysates and 80% in the cell surface fraction. Pim-1 depletion decreased apolipoprotein A-I-mediated [ 3 H]cholesterol efflux from HepG2 cells ( Figure 1B) , which reflects the function of ABCA1. [1] [2] [3] [4] 32 Apolipoprotein A-I-mediated [ 3 H] cholesterol efflux was 64% and 55% lower in Pim-1 siRNAtransfected HepG2 cells than in control siRNA-transfected HepG2 cells under normal and LXR agonist-treated condition, respectively. No significant difference in apolipoprotein A-I-mediated [ 3 H]cholesterol efflux from MPMs and bone marrow-derived macrophages (M0, M1, and M2) was detectable between control (Pim-1 +/+ ) and Pim-1 kinase activitydeficient (Pim-1 −/− ) mice ( Figure IB and ID in the online-only Data Supplement). mRNA expression of ABCA1 was unaffected by Pim-1 depletion in HepG2 cells ( Figure 1C ).
Presence of Pim-1L in Liver, but not in MPMs, and Decreased Expression of PIM1 mRNA Under Cholesterol-Depleted Conditions
To gain insight into the regulation of csABCA1 by Pim-1 under physiological and pathophysiological conditions, the expression of Pim-1L, the long isoform of Pim-1 that is tethered in the plasma membrane [29] [30] [31] and could affect csABCA1, was examined in livers and MPMs. The impact of the cellular cholesterol level on the amount of PIM1 mRNA was also evaluated in HepG2 cells.
In livers, Pim-1 was predominantly detected around 50 kDa, which is consistent with the reported molecular weight of Pim-1L, 28 and was enriched in liver plasma membranes (LPMs; Figure 2A ). By contrast, the membrane-tethering Nonstandard Abbreviations and Acronyms ABCA1/B1/G1/G2 ATP-binding cassette transporter A1/B1/G1/G2 Figure 2A through 2C). The band detected between 50 and 37 kDa in both cells was not derived from Pim-1 because it was not concentrated in the membrane fractions and was unaffected by transfection with Pim-1 siRNA ( Figure IA in the onlineonly Data Supplement). These findings indicate that Pim-1L is highly expressed in liver compared with MPMs and enterocytes. Treatment with lovastatin, a cholesterol-lowering agent, markedly decreased expression of PIM1 mRNA and ABCA1 mRNA, whereas T090137, LXR agonist, had no significant influence on the expression of PIM1 mRNA ( Figure 2D ).
Phosphorylation of ABCA1 by Pim-1 Through Direct Interaction Between Both Proteins
To examine whether ABCA1 is a substrate of Pim-1, immunoprecipitates with anti-FLAG antibody from HEK293T cells transfected with pcDNA3.1(+)-3×FLAG-ABCA1 or the corresponding empty vector were subjected to in vitro kinase assay, where the specimens were incubated in the presence of [γ-32 P]ATP with or without glutathione S-transferase-Pim-1S, which exhibits comparable in vitro kinase activity to Pim-1L. 28 Analysis of the products by SDS-PAGE followed by autoradiography showed that glutathione S-transferase-Pim-1S produced a single band above 250 kDa, which is the same molecular weight as ABCA1 ( Figure 1A ), in the immunoprecipitates from HEK293T cells with ectopic expression of 3×FLAG-ABCA1, but not those from mock-transfected cells ( Figure 3A ). The band disappeared by the addition of Pim-1 inhibitor to the in vitro kinase assay reaction mixture. The interaction between ABCA1 and Pim-1 was confirmed by the presence of HA-Pim-1L in immunoprecipitates obtained with anti-FLAG antibody from COS-1 cells expressing 3×FLAG-ABCA1 and HA-Pim-1L ( Figure 3B ). Consistent with the previous reports, [29] [30] [31] in immunocytochemistry, HA-Pim-1L was detected not only in cytoplasm but also just beneath the plasma membrane where 3×FLAG-ABCA1 was expressed ( Figure II in the online-only Data Supplement). All of these results suggested that Pim-1L phosphorylated ABCA1 through its direct interaction with ABCA1 at the plasma membrane.
Inhibition of Degradation of csABCA1 by Pim-1L Through Promotion of Interaction Between csABCA1 and LXRβ
Because Pim-1 had a more dominant effect on the abundance of ABCA1 in the cell surface fractions than that in the cell lysates ( Figure 1A ), its influence on the degradation of csABCA1 was investigated. The degradation of csABCA1 was markedly facilitated by depletion of Pim-1, but not of ABCA1, in HepG2 cells ( Figure 4A ; Figure III in the onlineonly Data Supplement), indicating that Pim-1 itself was implicated in the degradation of csABCA1. The amount of biotin-labeled ABCA1 remaining 4 and 8 hours after incubation was 25% and 2%, respectively, in the Pim-1-depleted HepG2 cells compared with 67% and 46% in the control cells. The accelerated degradation of csABCA1 was abrogated by ectopic expression of HA-Pim-1L ( Figure 4B ). Treatment with bafilomycin, an inhibitor of lysosomal degradation, eliminated the effect of the depletion of Pim-1 ( Figure 4C ). We previously reported that LXRβ reduces the susceptibility of csABCA1 to ubiquitination by its physical interaction with csABCA1 and thereby inhibits lysosomal degradation of csABCA1 through the ESCRT system. 21, 22 To explore the implication of Pim-1 in this machinery, the influence of Pim-1 depletion on the degradation of csABCA1 was determined after treatment with the LXR agonist GW3965, which facilitates the dissociation of LXRβ from csABCA1 and consequently its lysosomal degradation. 21 Pim-1 depletion accelerated the degradation of csABCA1 in HepG2 cells under normal culture conditions but not under GW3965-treated conditions ( Figure 5A ). Together with the observation that the amount of LXRβ in membrane fraction of HepG2 cells were decreased by 50% by Pim-1 depletion ( Figure 5B ), this result suggested that Pim-1 modulated the lysosomal degradation of csABCA1 co-operatively with LXRβ. It was corroborated by experiments using COS-1 cells with the ectopic expression of 207 HA-ABCA1 (which has an extracellular HA epitope tag between G207 and D208), HA-Pim-1L, and FLAG-LXRβ. In COS-1 cells expressing 207 HA-ABCA1, HA-Pim-1L had no impact on the degradation of csABCA1 in the absence of FLAG-LXRβ, but the degradation was delayed in its presence ( Figure 5C ). Furthermore, Western blot analysis of products from cell surface coimmunoprecipitation, in which only cs 207 HA-ABCA1 was precipitated because COS-1 cells expressing 207 HA-ABCA1 were subjected to reaction with anti-HA antibody before cell lysis, showed that HA-Pim-1L enhanced the interaction between 207 HA-ABCA1 and FLAG-LXRβ on the plasma membrane ( Figure 5D ). HA-Pim-1L expression induced 4.5-fold increase in the band intensity of FLAG-LXRβ in the immunoprecipitates. Consistent with the immunocytochemical findings ( Figure 3C ), the interaction of csABCA1 and Pim-1L was confirmed ( Figure 5D ). The kinase-inactive Pim-1L mutant (HA-DN-Pim-1L), 30 which enabled interaction with 207 HA-ABCA1 to a similar extent as HA-Pim-1L, had much less impact on the interaction between 207 HA-ABCA1 and FLAG-LXRβ on the plasma membrane than HA-Pim-1L. The cell surface coimmunoprecipitation analysis also revealed that FLAG-LXRβ enhanced the interaction between 207 HA-ABCA1 and HA-Pim-1L on the plasma membrane ( Figure 5E ).
Decreased ABCA1 Expression in LPMs and Decreased HDL Concentration in Plasma of Pim-1 −/− Mice
To demonstrate the in vivo relevance of the findings obtained from cells, Pim-1 −/− mice, which are deficient in Pim-1 kinase activity, were used. In the primary hepatocytes, the abundance of ABCA1 in the cell surface fraction was 50% lower in Pim-1 − /− mice than in Pim-1 +/+ mice. No change in its expression between both mice was observed in the cell lysate ( Figure  6A ). The reduced expression of ABCA1 in the cell lysates of Pim-1-depleted HepG2 cells, but not of the primary hepatocytes from Pim-1 −/− mice, could be explained by the fact that ABCA1 expression is relatively concentrated in the cell surface in HepG2 cells compared with its expression in primary hepatocytes. The ratio of ABCA1 in the cell lysate to ABCA1 in the cell surface fraction is 4-fold higher in HepG2 cells than that in the primary hepatocytes ( Figure IV in the online-only Data Supplement). Whereas expression of ABCA1 and LXRβ were not different between the liver homogenates from Pim-1 +/+ and Pim-1 −/− mice, it was 52% and 75% lower in the LPMs of Pim-1 −/− mice compared with the LPMs of Pim-1 +/+ mice ( Figure  6B ). This result supports regulatory mechanism of csABCA1 by Pim-1L and LXRβ in hepatocytes, which are drawn from experiments using COS-1 cells with exogenous expression of these proteins ( Figure 5C through 5E ). Consistent with finding no change in ABCA1 expression between Pim-1 +/+ mice and Pim-1 −/− mice in the cell lysate of the primary hepatocytes and the liver homogenates ( Figure 6A and 6B) , both mice showed similar expression levels of ABCA1 mRNA in liver ( Figure  6D ). In membrane fractions from enterocytes, ABCA1 expression was increased 1.5-fold in Pim-1 −/− mice compared with Pim-1 +/+ mice ( Figure 6C ). Hepatic ABCA1 predominantly contributes to the biogenesis of HDL particles and maintains the plasma HDL level. 6 The plasma HDL concentrations in Pim-1 −/− mice were ≈23% lower than those in Pim-1 +/+ mice ( Figure 6E ). Although the influence of Pim-1 deficiency on the plasma HDL level was smaller than that on the abundance of ABCA1, it could be explained by the increase in ABCA1 expression in membrane fractions from enterocytes of Pim-1 −/− mice ( Figure 6C ) because intestinal ABCA1 contributes to the formation of 30% of the plasma HDL pool in the steady state. 5
Discussion
In contrast to the growing body of research elucidating the mechanism of ABCA1 synthesis, much less is known about the molecular mechanism underlying its degradation. We previously reported that csABCA1 physically interacts with LXRβ and is thereby protected from ubiquitination and subsequent lysosomal degradation through the ESCRT system. 21, 22 This regulatory mechanism is independent of the pathway involving calpain and proteasome. 22 The current study integrated Pim-1L, a constitutively active serine/threonine-protein kinase, into our previous findings. In vitro studies using HepG2 cells and 207 HA-ABCA1expressing COS-1 cells suggested that Pim-1L facilitates the interaction between csABCA1 and LXRβ, resulting in inhibition of lysosomal degradation of csABCA1 through the ESCRT system and an increase in the expression and function of csABCA1 (Figures 1 and 3 through 5 ). Given that LXRβ has no postulated consensus phosphorylation sites for Pim-1 and increases the association of csABCA1 with Pim-1L ( Figure 5E ), it is possible that the Pim-1L-mediated phosphorylation of csABCA1 followed by the increased interaction with LXRβ stabilizes the csABCA1-Pim-1L complex itself. Therefore, Pim-1L and LXRβ could mutually facilitate formation of the complex with csABCA1 and efficiently protect csABCA1 from ubiquitination and subsequent lysosomal degradation (Figure 7) .
Pim-1L also increases the cell surface expression of ABCG2 and ABCB1 through their phosphorylation. 29, 31 However, the mechanism responsible differs from that for ABCA1, because Pim-1L-mediated phosphorylation assists the trafficking of ABCG2 to the plasma membrane by promoting homodimer formation, and that of ABCB1 by inhibiting proteosomal degradation in the endoplasmic reticulum. 29, 31 At present, how the phosphorylation of csABCA1 by Pim-1L makes it easier for csABCA1 to form a complex with LXRβ remains unclear. It could occur at or near the binding interfaces in csABCA1, which might affect the interaction between both proteins through recognition of a specific phosphorylated serine/threonine by LXRβ and the conferral of binding energy to csABCA1. 23, 24 Long-range conformational changes through allosteric mechanisms might also be induced by the phosphorylation of a site outside the interacting interfaces in csABCA1.
Consistent with the observations in vitro, Pim-1 −/− mice showed a 52% decrease in ABCA1 expression in LPMs and a concomitant 23% decrease in plasma HDL concentrations ( Figure 6B and 6E) . By contrast, in MPMs and bone marrow-derived macrophages from mice, Pim-1 had no apparent effect on the expression and function of ABCA1 ( Figure  I in the online-only Data Supplement). The hepatocyte-specific outcome of Pim-1 depletion could be explained by the much lower abundance of membrane-localized Pim-1L in macrophages than that in liver (Figure 2A and 2B ). Pim-1 is being studied intensively in the field of multiple human malignancies, including prostate cancers. 25, 26 This study identified for the first time the physiological function of Pim-1L in HDL homeostasis. The reason Pim-1 is indispensable for controlling the degradation of csABCA1 in hepatocytes, but not in macrophages, may be derived from the physiological function of ABCA1 in these cells. In macrophages, the cholesterol efflux pathway involving ABCA1 and ABCG1 contributes exclusively to the maintenance of cellular cholesterol homeostasis. 33, 34 By contrast, the cholesterol content in hepatocytes is determined not only by the efflux of cholesterol but also by its synthesis, catabolism to bile acids, and uptake. 35 The major role of hepatic ABCA1 is to mediate HDL biogenesis. Given the discrete functions of ABCA1, in macrophages, ABCA1 should be synthesized and degraded immediately to respond to changes in the cellular cholesterol content and thereby protect the macrophages; whereas, in hepatocytes, it is preferable to maintain cellular cholesterol homeostasis by regulating molecules other than ABCA1 involved in the synthesis, catabolism, and uptake of cholesterol, because changes in the circulating HDL level have a physiological impact on many Left, HepG2 cells were transfected with control short interfering RNA (siRNA) or Pim-1 siRNA. At 72 h after the transfection, the cells were biotinylated, incubated for 8 h at 37 °C in the absence or presence of LXR agonist (GW3965, 1 μmol/L), and then analyzed as described in other tissues and the liver. This hypothesis is corroborated by the finding that the accumulation of cellular cholesterol induces more ABCA1 transcripts involving LXR in peripheral cells, like macrophages, than in hepatocytes, [36] [37] [38] and that the half-life of csABCA1 is longer in HepG2 cells than that in MPMs (8 hours in HepG2 cells and 4 hours in MPMs 21 ). Therefore, it is conceivable that the phosphorylation of csABCA1 by Pim-1L is needed in hepatocytes only to confer As expected, because Pim-1 is a target of miR-33, 39 which is present in the intron of SREBP-2 and induced by cholesterol depletion, 14, 15 mRNA expression of Pim-1 was decreased under cholesterol-depleted conditions ( Figure 2D ). miR-33 controls cholesterol homeostasis by targeting genes implicated in cholesterol transport, including ABCA1. Delivery of miR-33 into mice causes a 22% decrease in the plasma HDL level by reducing the hepatic expression of ABCA1. 15 Therefore, hepatic ABCA1 might be suppressed by miR-33 directly during the synthetic process through destabilization of ABCA1 mRNA and repression of its translation and indirectly during the degradation process by facilitating the lysosomal degradation of csABCA1 by a decrease in Pim-1L expression ( Figure 7) . By contrast with the depletion of cellular cholesterol, treatment with the LXR agonist had no significant impact on PIM1 level ( Figure 2D ). From the viewpoint of cell protection, it seems disadvantageous to facilitate degradation of csABCA1 under conditions of high cellular cholesterol because this adaptation decreases expression of csABCA1 and cholesterol efflux by ABCA1, which induces cell toxicity by abnormal deposition of cellular cholesterol. However, given that the cellular cholesterol level in hepatocytes is modulated by its synthesis, catabolism to bile acids, and uptake, as well as its efflux by ABCA1, and that transcription of ABCA1 mRNA is markedly induced in response to cholesterol accumulation, the machinery identified in the current study might contribute to limiting variation of circulating HDL by acutely increasing hepatic ABCA1 expression.
In conclusion, our current study suggests that Pim-1L interacts with and phosphorylates csABCA1, which facilitates the interaction between csABCA1 and LXRβ and thereby prevents its ubiquitination and subsequent lysosomal degradation through the ESCRT system. Given that the interaction of the phosphorylated csABCA1 by Pim-1L with LXRβ stabilizes the csABCA1-Pim-1L complex, this machinery composes the positive feedback loop to protect csABCA1 efficiently from ubiquitination. Through this molecular mechanism, Pim-1 regulates the hepatic expression of ABCA1 and circulating HDL levels. There is an inverse relationship between plasma HDL concentration and atherosclerotic cardiovascular disease risk. 40 Therefore, there has been great interest in targeting HDL therapeutically. Our findings point to the possibility that modulating the molecular mechanism underlying lysosomal degradation of csABCA1 may be a rational strategy to increase hepatic ABCA1 expression and raise circulating HDL levels. Ubiquitination acts as a signal for the sorting of internalized csABCA1 to lysosomal degradation in the early endosome. 22 The ubiquitination of substrate proteins is mediated by the covalent attachment of ubiquitin via the sequential action of 3 enzymes: a ubiquitin-activating enzyme E1, a ubiquitinconjugating enzyme E2, and a ubiquitin ligase E3. 41 these 3 enzymes, E3 is considered the enzyme that ensures the correct timing, localization, and specificity of the ubiquitination reaction. 41 The E3 ubiquitin ligase inducible degrader of the low-density lipoprotein receptor (IDOL), which is transcriptionally regulated by cellular cholesterol level through LXR, controls the amount of low-density lipoprotein receptor, and thereby affects cholesterol homeostasis. The abundance of hepatic low-density lipoprotein receptor in Pim-1 −/− mice was the same as in Pim-1 +/+ mice ( Figure 6A ). Therefore, it is likely that the ubiquitination of csABCA1 is mediated independently of the LXR-Idollow-density lipoprotein receptor axis. 38 Further studies to identify and characterize the E3 ligases that mediate ubiquitination of csABCA1 should pave the way to modulating the lysosomal degradation of csABCA1 and realizing HDLtargeted therapies. Because LXRβ inhibits ubiquitination of csABCA1 through its physical interaction and consequently the lysosomal degradation of csABCA1 involving the endosomal sorting complex required for transport (ESCRT) system, 21, 22 the machinery composed of Pim-1L, and LXRβ is the positive feedback loop to protect csABCA1 efficiently from ubiquitination and consequently controls the abundance of csABCA1 and high-density lipoprotein (HDL) biogenesis. The expression of Pim-1L alters depending on the cellular cholesterol level. Thus, Pim-1L contributes to the regulation of HDL homeostasis. E3s indicates ubiquitin ligases; and P, phosphorylation.
